Myomo shares tumbled 42% after-hours as the wearable medical robotics maker cut its 2025 revenue forecast to $40-42 million from $50-53 million and posted a wider Q2 loss. Weaker lead quality, slower conversions, and higher costs hurt results. Operating expenses surged 65%, and backlog fell 18%.